Abstract
The role of insulin-like growth factor binding protein 2 (IGFBP2) in cancer is unclear. In general, IGFBP2 is considered to be oncogenic and its expression is often observed to be elevated in cancer. However, there are a number of conflicting reports in vitro and in vivo where IGFBP2 acts in a tumor suppressor manner. In this mini-review, we discuss the factors influencing the variation in IGFBP2 expression in cancer and our interpretation of these findings.
| Original language | English |
|---|---|
| Pages (from-to) | 25 |
| Journal | Frontiers in Endocrinology |
| Volume | 6 |
| Issue number | 25 |
| Early online date | 27 Feb 2015 |
| DOIs | |
| Publication status | Published - Feb 2015 |
Access to Document
- IGF-binding protein 2 – oncogene or tumor suppressor?
Copyright © 2015 Pickard and McCance. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.